IRIS
BUGATTI, SERENA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.574
AS - Asia 3.008
EU - Europa 2.075
SA - Sud America 445
AF - Africa 110
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 2
Totale 9.221
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.471
CN - Cina 1.152
SG - Singapore 727
IE - Irlanda 473
VN - Vietnam 421
HK - Hong Kong 362
BR - Brasile 328
RU - Federazione Russa 302
DE - Germania 270
FI - Finlandia 241
IT - Italia 208
UA - Ucraina 133
FR - Francia 129
GB - Regno Unito 99
SE - Svezia 90
IN - India 74
ZA - Sudafrica 60
CA - Canada 57
BD - Bangladesh 49
AR - Argentina 33
AE - Emirati Arabi Uniti 23
JP - Giappone 23
MX - Messico 23
CO - Colombia 21
EC - Ecuador 21
TR - Turchia 21
BE - Belgio 18
ES - Italia 18
ID - Indonesia 18
PK - Pakistan 18
VE - Venezuela 18
IQ - Iraq 16
IR - Iran 14
NL - Olanda 14
SA - Arabia Saudita 14
CZ - Repubblica Ceca 13
MY - Malesia 13
PL - Polonia 13
AT - Austria 11
LT - Lituania 10
MA - Marocco 10
EG - Egitto 9
PH - Filippine 9
UZ - Uzbekistan 9
PE - Perù 8
CL - Cile 7
KE - Kenya 7
IL - Israele 6
TH - Thailandia 6
RO - Romania 5
SK - Slovacchia (Repubblica Slovacca) 5
TN - Tunisia 5
AL - Albania 4
AU - Australia 4
BG - Bulgaria 4
BO - Bolivia 4
CR - Costa Rica 4
JM - Giamaica 4
AZ - Azerbaigian 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
ET - Etiopia 3
GR - Grecia 3
JO - Giordania 3
KG - Kirghizistan 3
KZ - Kazakistan 3
NZ - Nuova Zelanda 3
PA - Panama 3
PS - Palestinian Territory 3
SN - Senegal 3
TT - Trinidad e Tobago 3
UY - Uruguay 3
CU - Cuba 2
CY - Cipro 2
EU - Europa 2
HN - Honduras 2
HU - Ungheria 2
KR - Corea 2
KW - Kuwait 2
LK - Sri Lanka 2
NG - Nigeria 2
NP - Nepal 2
OM - Oman 2
PT - Portogallo 2
PY - Paraguay 2
SY - Repubblica araba siriana 2
ZM - Zambia 2
BB - Barbados 1
BY - Bielorussia 1
CH - Svizzera 1
CI - Costa d'Avorio 1
DK - Danimarca 1
EE - Estonia 1
HR - Croazia 1
KH - Cambogia 1
LB - Libano 1
LV - Lettonia 1
MK - Macedonia 1
MR - Mauritania 1
NA - Namibia 1
Totale 9.214
Salva come PNG Salva come JPEG
Città #
Dublin 467
San Jose 443
Chandler 415
Singapore 395
Hong Kong 349
Dallas 319
Ashburn 318
Beijing 250
Jacksonville 195
Nanjing 195
Ho Chi Minh City 137
Boardman 124
Helsinki 113
Hanoi 104
Munich 102
New York 102
Lauterbourg 101
Los Angeles 91
Princeton 81
Lawrence 75
Wilmington 75
Nanchang 68
Ann Arbor 64
Council Bluffs 60
Shenyang 59
Shanghai 57
Medford 51
Hebei 50
Changsha 49
Johannesburg 49
Moscow 49
Da Nang 45
Milan 45
Buffalo 42
Redondo Beach 42
Turku 42
Jiaxing 36
Pavia 30
São Paulo 30
Santa Clara 27
Hangzhou 25
Montreal 25
Orem 24
Tianjin 21
Tokyo 20
Dubai 19
Piscataway 19
Brussels 18
London 18
Seattle 18
The Dalles 18
Woodbridge 18
Chennai 17
Denver 17
Rio de Janeiro 17
Toronto 17
Brooklyn 14
Frankfurt am Main 14
Columbus 13
Haiphong 12
Stockholm 12
Tabriz 12
Fairfield 11
Falkenstein 11
Norwalk 11
Nuremberg 11
Warsaw 11
Atlanta 10
Manchester 10
Poplar 10
Chicago 9
Guangzhou 9
Houston 9
Mexico City 9
Baghdad 8
Belo Horizonte 8
Medellín 8
Mumbai 8
Quito 8
Verona 8
Washington 8
Zhengzhou 8
Amsterdam 7
Berlin 7
Phoenix 7
Phủ Lý 7
Biên Hòa 6
Brno 6
Bến Tre 6
Elk Grove Village 6
Guayaquil 6
Jeddah 6
Kuala Lumpur 6
Nairobi 6
Porto Alegre 6
San Francisco 6
Tashkent 6
Bangkok 5
Boston 5
Cape Town 5
Totale 6.028
Salva come PNG Salva come JPEG
Nome #
Assessment of synovitis to predict bone erosions in rheumatoid arthritis 152
B cells in rheumatoid arthritis. 146
Anti-neutrophil cytoplasmic antibodies (ANCA) ( Review ) [Anticorpi anticitoplasma dei neutrofili (ANCA)] 143
B cells in rheumatoid arthritis: from pathogenic players to disease biomarkers 140
Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis 139
Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis 138
In early inflammatory polyarthritis more intensive management according to the 2010 ACR/EULAR criteria leads to higher rates of clinical remission: Comparison of two cohorts treated according to different treat to target protocols 138
Analysis of the apolipoprotein(a) size polymorphism in patients with systemic lupus erythematosus. 129
Analysis of the apolipoprotein(a) size polymorphism in patients with systemic lupus erythematosus 124
Analysis of the apoliporotein(a) size polymorphism in patients with systemic lupus erythematosus 121
B cells in rheumatoid arthritis. 121
CCL21 expression pattern of human secondary lymphoid organ stroma is conserved in inflammatory lesions with lymphoid neogenesis 119
Reactogenicity, safety and disease flares following BNT162b2 mRNA COVID-19 vaccine in patients with chronic immune-inflammatory arthritis treated with biological and targeted synthetic disease-modifying anti-rheumatic drugs 118
Clinical, Imaging, and Pathological Suppression of Synovitis in Rheumatoid Arthritis: Is the Disease Curable? 115
Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. 112
Ultrasonographic and MRI characterisation of the palindromic phase of rheumatoid arthritis 112
Autoantibodies to heterogeneous nuclear ribonucleoproteins. 111
B cell autoimmunity and bone damage in rheumatoid arthritis 110
Janus kinase inhibitors effectively improve pain across different disease activity states in rheumatoid arthritis 109
A Multicenter Retrospective Analysis Evaluating Performance of Synovial Biopsy Techniques in Patients With Inflammatory Arthritis: Arthroscopic Versus Ultrasound-Guided Versus Blind Needle Biopsy 109
Correspondence on 'EULAR December 2020 viewpoints on SARS-CoV-2 vaccination in patients with RMDs' 109
Challenges in the diagnosis of early rheumatoid arthritis in times of COVID-19 108
Subclinical remodelling of draining lymph node structure in early and established rheumatoid arthritis assessed by power Doppler ultrasonography 106
B cell synovitis and clinical phenotypes in rheumatoid arthritis: relationship to disease stages and drug exposure 105
Cytokine profile, ferritin, and multi-visceral involvement characterise macrophage activation syndrome during adult-onset Still's disease 101
A case of a rheumatoid nodule on the aortic valve in a patient with rheumatoid arthritis in sustained remission with anti-TNFα 100
Adult-onset Still's disease with elderly onset, results from a multicentre study 100
Personalized Therapeutic Strategies in the Management of Osteoporosis in Patients with Autoantibody-Positive Rheumatoid Arthritis 98
null 97
What can we learn from treatment-induced changes in rheumatoid factor and anti-citrullinated peptide antibodies? 95
No evidence of short-term impact of repeated BNT162b2 vaccination on rheumatoid arthritis homeostasis in drug-free remission 94
Inflammatory correlates of the Patient Global Assessment of Disease Activity vary in relation to disease duration and autoantibody status in patients with rheumatoid arthritis 93
Vitamin D 25OH Deficiency and Mortality in Moderate to Severe COVID-19: A Multi-Center Prospective Observational Study 93
Established rheumatoid arthritis. The pathogenic aspects. 93
Impact of Anti-Citrullinated Protein Antibodies on Progressive Systemic Bone Mineral Density Loss in Patients With Early Rheumatoid Arthritis After Two Years of Treat-to-Target 93
Long term treatment of rheumatoid arthritis with rituximab 92
Insights Into the Concept of Rheumatoid Arthritis Flare 92
Subchondral Bone Marrow Inflammatory Involvement in Rheumatoid Arthritis: Lymphoid Neogenesis and In Situ Relationship with Subchondral Bone Marrow Osteoclasts 91
Long term treatment of rheumatoid arthritis with rituximab. 90
A “Window of Therapeutic Opportunity” for Anti-Cytokine Therapy in Patients With Coronavirus Disease 2019 90
Nuovi aspetti patogenetici dell’artrite reumatoide 89
Involvement of subchondral bone marrow in rheumatoid arthritis: lymphoid neogenesis and in situ relationship to subchondral bone marrow osteoclast recruitment 88
Dupilumab-induced enthesoarthritis and refractory atopic dermatitis successfully treated with baricitinib 88
B cell synovitis and clinical phenotypes in rheumatoid arthritis: relationship to disease stages and drug exposure 88
Seronegative autoimmune diseases: A challenging diagnosis 87
Cost-effectiveness of the early arthritis clinic organizational model: the ELECTRA study 87
Treatment comparison in rheumatoid arthritis: Head-to-head trials and innovative study designs 87
The draining lymph node in rheumatoid arthritis: current concepts and research perspectives 87
Administrative Databases and Diagnostic Therapeutic and Assistance Paths -PDTA- in the Monitoring Treatment of Rheumatoid Arthritis: The Experience of ATS Pavia 87
What can we learn from treatment-induced changes in rheumatoid factor and anti-citrullinated peptide antibodies? 85
Limiting factors to Boolean remission differ between autoantibody-positive and -negative patients in early rheumatoid arthritis 85
Synovial tissue heterogeneity and peripheral blood biomarkers 84
Early treatment in early undifferentiated arthritis 84
Anti-neutrophil cytoplasmic antibodies (ANCA) 83
High serum levels of CXCL13 predict lower response to csDMARDs in both ACPA-positive and ACPA-negative early rheumatoid arthritis 82
Polyarthrite rhumatoïde associée à un trait bêta-thalassémique : aspect clinique, sérologique et immunogénétique 82
Estimated 10-year cardiovascular risk in a large Italian cohort of rheumatoid arthritis patients: Data from the Cardiovascular Obesity and Rheumatic DISease (CORDIS) Study Group 82
Clinical Features of Diabetes Mellitus on Rheumatoid Arthritis: Data from the Cardiovascular Obesity and Rheumatic DISease (CORDIS) Study Group 81
Timely escalation to second-line therapies after failure of methotrexate in patients with early rheumatoid arthritis does not reduce the risk of becoming difficult-to-treat 80
Synovial and serum B-cell signature of autoantibody-negative rheumatoid arthritis versus autoantibody-positive rheumatoid arthritis and psoriatic arthritis 80
Prediction of long-term drug-free outcomes in ACPA-positive and ACPA-negative rheumatoid arthritis by combined clinical and ultrasound assessment of residual disease: a 5-year prospective study 80
Use of ultrasound-guided small joint biopsy to evaluate the histopathologic response to rheumatoid arthritis therapy: recommendations for application to clinical trials 80
Serum levels of CXCL13 are associated with ultrasonographic synovitis and predict power Doppler persistence in early rheumatoid arthritis treated with non-biological disease-modifying anti-rheumatic drugs 79
Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. Efficacy 79
Controversies over hydroxychloroquine in the prevention of SARS-CoV-2 infection put rheumatologists on the frontline 79
Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA 78
Tumor necrosis factor-α inhibitor-related autoimmune disorders 77
The constitutive pattern of CCL21 production is maintained in inflammatory lesions with lymphoid neogenesis 76
The novel cytokine interleukin-36α is expressed in psoriatic and rheumatoid arthritis synovium 75
Power Doppler ultrasonographic assessment of the joint-draining lymph node complex in rheumatoid arthritis: a prospective, proof-of-concept study on treatment with tumor necrosis factor inhibitors. 75
Differences and similarities in rheumatology specialty training programmes across European countries 75
Do we need Early Arthritis Clinics to counteract the excess of mortality in rheumatoid arthritis? 74
Clinical Applications of Synovial Biopsy. 74
Autoantibody-negative rheumatoid arthritis: still a challenge for the rheumatologist 72
Rheumatology training experience across Europe: Analysis of core competences 72
In patients with early peripheral psoriatic arthritis baseline c-reactive protein, pain and ultrasound-detected synovitis predict subsequent treatment with ts/bdmards. A retrospective analysis 71
Progressive increase in time to referral and persistently severe clinical presentation over the years in autoantibody-negative patients with rheumatoid arthritis in the setting of an early arthritis clinic 71
Rheumatoid arthritis treatment: the earlier the better to prevent joint damage 70
High expression levels of the B cell chemoattractant CXCL13 in rheumatoid synovium are a marker of severe disease 70
Tender joints in early autoantibody-negative rheumatoid arthritis: Should they be included in the scoring of joint involvement of the 2010 ACR/EULAR classification criteria? 69
Rheumatoid arthritis in beta-thalassemic trait: clinical, serologic and immunogenetic profile. 69
Long-term safety of abatacept in patients with rheumatoid arthritis 68
La linfoneogenesi 68
Over-expression of miR-223 in T-lymphocytes of early rheumatoid arthritis patients 68
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial 68
Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab: results from the Italian GISEA registry 68
Role of lymphoid chemokines in the development of functional ectopic lymphoid structures in rheumatic autoimmune diseases 67
Modulating the co-stimulatory signal for T cell activation in rheumatoid arthritis: Could it be the first step of the treatment? 66
Seronegative rheumatoid arthritis: one year in review 2023 65
Early disease control by low-dose prednisone comedication may affect the quality of remission in patients with early rheumatoid arthritis. 65
The access route through the anatomical snuffbox in ultrasound-guided synovial biopsy of the wrist allows for a safe and effective collection of tissue samples in inflammatory arthritis 64
Evaluation of Minimally Invasive, Ultrasound-guided Synovial Biopsy Techniques by the OMERACT Filter-Determining Validation Requirements 64
Seronegative rheumatoid arthritis: Neglected in clinical trials, a giant in clinical practice 63
The Clinical Value of Autoantibodies in Rheumatoid Arthritis. 63
Baseline Serum Concentrations of TRAIL in Early Rheumatoid Arthritis: Relationship with Response to Disease-modifying Antirheumatic Drugs. 62
Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis 61
Comorbidities in the Spondyloarthritis GISEA Cohort: an average treatment effect analysis on patients treated with bDMARDs 59
Increasing the threshold for patient global assessment in defining remission may have a different impact in patients with early and established rheumatoid arthritis 57
Inflammatory lesions in the bone marrow of rheumatoid arthritis patients: a morphological perspective 54
Influence of initial glucocorticoid co-medication on mortality and hospitalization in early inflammatory arthritis: an investigation by record linkage of clinical and administrative databases 53
Totale 8.910
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.996
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.996
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202111 0 0 0 0 0 0 0 0 0 0 0 11
2021/2022362 4 3 12 14 10 26 15 23 19 8 54 174
2022/20231.352 143 103 11 86 104 126 1 72 529 20 50 107
2023/2024626 46 182 22 30 53 149 23 34 11 12 31 33
2024/20251.775 43 111 24 24 21 110 124 101 468 94 236 419
2025/20264.057 307 273 458 374 461 147 862 228 325 279 203 140
Totale 9.585